New drug delivery solutions for pain management and infection control.
Our purpose is to alleviate inadequate pain management and surgical site infections through our innovative technologies.
Site-specific Pain Relief Without Opioids
Our innovative solid-state eutectic implant offers a transformative solution for sustained, non-opioid postoperative pain management.
Beyond Surgery – A Platform for Lasting Innovation
Our versatile technology is poised to drive revolutionary improvements across healthcare applications.
Infection Control with Next-Gen Antimicrobial Sutures
Our biodegradable eutectic antimicrobial sutures represent a groundbreaking advancement in infection prevention.
Transforming Surgical Recovery with Innovation in Pain and Infection Control
Each year, over 300 million surgeries are performed worldwide, with up to 75% of patients experiencing moderate to severe postoperative pain, yet less than half report satisfactory pain control.
Abdominal surgeries, accessing the peritoneal cavity, represent a large proportion of these procedures. In 2023 alone, an estimated 115 million peritoneal surgeries were performed. Infusion of lidocaine into the peritoneal cavity (< 72 hours) has shown promise but is associated with risk of infection and significant costs in healthcare support. Additionally, current reliance on opioids in healthcare systems results in significant side effects and the risk of addiction for patients. While smaller doses are often prescribed to mitigate these risks, they frequently lead to inadequate pain relief, leaving many patients with unaddressed discomfort.
Surgical site infections (SSIs) also pose a significant issue for postoperative recovery. Affecting up to 40 % of all surgeries, they impose a significant burden on healthcare systems due to the need for repeat surgeries, prolonged hospital stays and development of antimicrobial resistance.
Our mission is to change the current landscape of postoperative care. Leveraging innovative eutectic technology, our team is pioneering a dual approach to enhance postoperative recovery and patient outcomes.
Beyond Surgery – A Platform for Lasting Innovation
Our versatile technology is poised to drive revolutionary improvements across healthcare applications, creating potential for a wide portfolio of therapies with localised and sustained delivery options.
Our vision: faster recoveries, effective pain management, and a worry-free path back to everyday life. Through our advancements, we aim to restore patients’ well-being, faster and with fewer complications.
EutecPlatform
Site-specific Pain Relief Without Opioids
Our innovative solid-state eutectic implant offers a transformative solution for sustained, non-opioid postoperative pain management. Designed specifically for peritoneal surgery applications, we address key challenges in current practice.
Key features of our technology include:
Prolonged Drug Release
Solid-State Eutectic Technology
Opiod-Free Pain Relief
Improved Patient Outcomes
Our implant represents a significant step forward in advancing postoperative care, combining innovative technology with patient safety and comfort to redefine standards in non-opioid pain management.
EutecThread
Infection Control with Next-Gen Antimicrobial Sutures
Our biodegradable eutectic antimicrobial sutures represent a groundbreaking advancement in infection prevention. They significantly outperform existing antimicrobial sutures, which often achieve less than 30% effectiveness.
Key advantages of our technology include:
Enhanced Drug Loading
Sustained Efficacy
Dual-Drug Combination
Combatting Antimicrobial Resistance
Our technology redefines the standard for antimicrobial sutures, providing superior localised infection prevention and addressing critical unmet needs in postoperative care.
Our Technology
Stay up to date with us!
Latest News
November 2024
Our implant technology is moving into a small-scale Phase 1 trial in June 2025. Our preclinical and clinical trials are led by Professor Andrew Hill of the University of Auckland.
To stay up to date with the results of our trial by signing up to email updates below.
December 2020
Eutectic implant shows promising preclinical trial results – read more below.
https://linkinghub.elsevier.com/retrieve/pii/S0142961220306554
Who do we want to talk to?
Choose your area below!
For Patients
We value patient-centered research and would love to hear your insights. Your input could shape future advancements in postoperative care and improve the lives of others.
Please take a moment to complete the short survey below to help us make a difference.
Survey
For Healthcare Professionals
We value the expertise of healthcare professionals in shaping our research. Your insights are crucial to advancing postoperative care and improving patient outcomes.
Please take a moment to complete the survey below & help drive meaningful progress.
Survey
For Collaborators & Investors
We are actively seeking collaborators and investors to help bring our innovative solutions to life. Your support could accelerate advancements in postoperative care, improving outcomes for patients worldwide.
If you’re interested in exploring partnership opportunities, please connect below.
We would love to hear from you!
If you have any questions about our potential solution, or would like to speak further, please get in touch with our team.
Meet Our Team
Prof. David Jones
Co-Principal Investigator
Professor David Jones of Queen’s University Belfast, has over 30 years in pharmaceutical product development, and has been involved in the commercialisation of 70+ products. He is co-founder of two spinouts: Xiomateria and Re-Vana Therapeutics, which have been the recipients of multiple innovation awards. He is co-founder of two spinouts: Xiomateria and Re-Vana Therapeutics, which have been the recipients of multiple innovation awards.
Prof. Andrew Hill
Surgical Team Lead
Our preclinical and clinical trials are led by Professor Andrew Hill of the University of Auckland. As the past president of the International Society of Surgery, he is widely recognised for his contributions to surgical research and global leadership in the field.
Dr. Shu Li
Co-Principal Investigator
Dr. Shu Li specialises in developing novel pharmaceutical dosage forms using continuous manufacturing techniques like hot-melt extrusion and multilayer co-extrusion to enhance drug bioavailability and clinical efficacy. Her research focuses on amorphous solid dispersions, pharmaceutical cocrystals, and customisable formulations for precision medicine. Dr. Li employs advanced analytical techniques to understand multi-component interactions and optimise drug performance.
Dr. Darren Svirskis
Surgical Team Lead
Associate Head (Research) at the University of Auckland, develops bioelectronic implants and sustained drug delivery systems to treat spinal cord injuries and post-surgical pain. With over 100 publications, his work focuses on translating innovative therapies into real-world solutions.
Prof. Gavin Andrews
Co-Principal Investigator
Professor Gavin Andrews, Chair of Pharmaceutical Engineering, focuses on innovative oral dosage forms, biomaterials, and advanced manufacturing technologies like hot melt extrusion. His research emphasises quality-by-design approaches for drug delivery and solubility enhancement, supported by over £1M in funding and strong industry collaborations. Widely published and active internationally, he bridges academia and industry to advance pharmaceutical engineering.
Miss Katie Glover
Entrepreneurial Lead
Miss Katie Glover, a Research Assistant at Queen’s University Belfast, is the Entrepreneurial Lead in the Innovate UK market discovery program. She has extensive experience in collaborations with industrial partners and has led interdisciplinary projects which have gained mainstream media attention.